Adults 18 to 64, any sex, with Schizophrenia or Schizo Affective Disorder. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
The State Social Paranoia Scale (SSPS)Primary· The assessment was completed before the stimulation and 30 minutes after completion of the active/sham stimulation
Paranoid ideation was measured by the State Social Paranoia Scale (SSPS). Participants indicated how much they agree with each of 20 statements (e.g., "Someone was hostile towards me", "Someone was trying to isolate me") using a 5-point Likert scale (1 = do not agree, 5 = totally agree). Scores range from 20-100, and higher scores represent higher state paranoid ideation.
Group
Value
95% CI
Active Visit
9.72
± 14.61
Sham Visit
3.90
± 11.56
Ecological Momentary Assessment (EMA)-Based ParanoiaPrimary· Change in daily paranoia feelings was assessed from the pre-stimulation EMA period (7 days before the stimulation visit) to the post-stimulation EMA period (7 days after the stimulation visit)
Paranoid ideation was measured by Ecological Momentary Assessment (EMA), which involved questions about feelings of paranoia in daily life. The paranoia-related question is as follows: "Since the past alarm, how much have you had thoughts that you really can't trust other people?" The score for this item ranges from 1 to 7, with a higher score indicating a higher level of paranoid thinking.
Group
Value
95% CI
EMA-baseline
3.78
± 1.72
EMA-active
3.61
± 0.91
EMA-sham
3.96
± 1.85
Birchwood Social Functioning Scale (SFS)Primary· The assessment was completed 30 minutes after completion of the active/sham stimulation
Social functioning was measured by the Birchwood Social Functioning Scale (SFS). This scale measures social adjustment based on self-reports (4- or 5-point scales), with higher total scores indicating better social functioning (range = 0-223).
Group
Value
95% CI
Active Visit
114.21
± 22.35
Sham Visit
114.59
± 27.54
Ecological Momentary Assessment (EMA)-Based Social FunctioningPrimary· Change in daily interactions was assessed from the pre-stimulation EMA period (7 days before the stimulation visit) to the post-stimulation EMA period (7 days after the stimulation visit)
Social functioning was measured by Ecological Momentary Assessment (EMA) (i.e., questions about daily interactions with others). Two subscores were generated: social interaction frequency (score ranges from 0-5, a higher score indicates more frequent social interactions), social interaction motivation and experience (scores range from 1-7, a higher score indicates higher motivations to interact with others and better experiences during these interactions).
Social interaction frequency
Group
Value
95% CI
EMA-baseline
0.97
± 0.76
EMA-active
0.91
± 0.83
EMA-sham
0.92
± 0.90
Social interaction motivation and experience
Group
Value
95% CI
EMA-baseline
3.74
± 1.62
EMA-active
4.08
± 1.68
EMA-sham
3.71
± 1.62
The Trustworthiness TaskSecondary· The assessment was completed 30 minutes after completion of the active/sham stimulation
Paranoid ideation was measured by the Trustworthiness Task. This task requires participants to indicate how much they trust each of 60 grayscale facial stimuli along a 7-point Likert scale (-3 = very untrustworthy, 3 = very trustworthy). Total scores were calculated by averaging across responses and hence varied from -3 to +3, with higher values indicating a greater tendency to trust others.
Group
Value
95% CI
Active Visit
0.07
± 1.16
Sham Visit
-0.18
± 0.99
The Scrambled-sentences Task (SST)Secondary· The assessment was completed 30 minutes after completion of the active/sham stimulation
Paranoid ideation was measured by the Scrambled-sentences task (SST). This task measures the level of paranoia by asking participants to create sentences of either paranoid or nonparanoid meanings, with a greater percentage indicating a higher level of paranoid interpretation bias (range = 0-1).
Group
Value
95% CI
Active Visit
0.46
± 0.29
Sham Visit
0.49
± 0.28
The Ambiguous Intentions Hostility Questionnaire (AIHQ)Secondary· The assessment was completed 30 minutes after completion of the active/sham stimulation
Paranoid ideation was measured by the Ambiguous Intentions Hostility Questionnaire (AIHQ). Three subscores were generated: AIHQ (blame) (ranging from 3-16, with a higher score indicating a higher level of blaming tendency), AIHQ (hostility) (ranging from 1-5, with a higher score indicating a higher level of hostility), AIHQ (aggression) (ranging from 1-5, with a higher score indicating a higher level of aggression).
AIHQ (blame)
Group
Value
95% CI
Active Visit
8.28
± 3.07
Sham Visit
8.89
± 3.22
AIHQ (hostility)
Group
Value
95% CI
Active Visit
2.09
± 0.75
Sham Visit
2.35
± 0.78
AIHQ (aggression)
Group
Value
95% CI
Active Visit
1.75
± 0.40
Sham Visit
1.78
± 0.39
The Hostility Scale of the Personality Inventory for DSM-5 (PID-5-HS)Secondary· The assessment was completed 30 minutes after completion of the active/sham stimulation
Paranoid ideation was measured by the Hostility Scale of the Personality Inventory for DSM-5 (PID-5-HS). PID-5-HS contains 10 self-report items assessing pathological hostility. A total score (range from 0-30) was generated to reflect overall hostility level, with higher total scores indicating more hostility.
Group
Value
95% CI
Active Visit
9.42
± 7.56
Sham Visit
11.30
± 7.57
Sponsor's own description
The purpose of this study is to understand the relationship between psychotic symptoms and social functioning in individuals with schizophrenia spectrum disorders. Our goal is to determine whether stimulating the brain using transcranial Direct Current Stimulation (tDCS) can improve symptoms and daily functioning.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07400939 — Brain Stimulation Combined With Watching Hand Movements to Improve Hand Recovery in Chronic Stroke
· NA
· recruiting
NCT06994390 — Neuropathic Pain Intervention With tDCS in Brazilian Military Personnel (NeuBRAIN Trial)
· NA
· not yet recruiting
NCT07358832 — Neuromodulation Through Multisensory Stimulation for Visual Field Deficits in the Subacute Stage of Disease
· NA
· recruiting
NCT07331779 — Effect of tDCS Timing on Motor Recovery in Acute Stroke Rehabilitation
· NA
· not yet recruiting
NCT06972368 — Home-Based tDCS for Depression in BPD
· NA
· recruiting
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au
· Phase 3
· recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
· Phase 2
· recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
· recruiting
NCT06758414 — CBT-CP for Veterans With SMI
· NA
· recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis
· NA
· recruiting
Other The University of Texas at Dallas trials
Trials by the same sponsor.
NCT07534397 — Treatment of Cognitive and Sensorimotor Deficits in Parkinson's Disease With High Definition Transcranial Direct Current
· NA
· not yet recruiting
NCT07354139 — Using Non-invasive Brain Stimulation to Explore Potential Treatments to Reduce Speech Errors in Adults Who Stutter
· NA
· recruiting
NCT07206550 — The Role of Framing and Choice Architecture in Patients' Reactions and EHR Error Discovery and Reporting
· NA
· enrolling by invitation
NCT06731452 — Exploring Neurophysiological Markers of Brain Health
· NA
· recruiting
NCT06724887 — Brain Health on College Campuses
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas at Dallas
Last refreshed: 26 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05746494.